<DOC>
	<DOCNO>NCT02558829</DOCNO>
	<brief_summary>The Macimorelin-GHST ( growth hormone stimulation test ) compare ITT ( insulin tolerance test ) open-label , randomize , 2-way crossover Trial . The trial include subject suspect adult growth hormone deficiency ( AGHD ) group healthy control subject .</brief_summary>
	<brief_title>Validation Macimorelin Test Adult Growth Hormone Deficiency</brief_title>
	<detailed_description>Trial subject assign group descend likelihood AGHD : Group A , B , C : High , intermediate , low likelihood GHD , respectively ; Group D : Healthy control subject match Group A subject . The sequential order GHSTs suspect AGHD subject ( Group A-C ) determine stratified randomization ; healthy control subject ( Group D ) test sequence match Group A subject . Serum concentration GH measure pre-defined time point GHST macimorelin insulin . A peak GH value GHST-specific cut-off value consider 'test positive ' . The ITT consider comparator ( non-reference standard ) ass positive negative agreement GHSTs , base predefined cut-off value .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Septo-Optic Dysplasia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Suspected growth hormone deficiency ( GHD ) , base either follow : structural hypothalamic pituitary disease , surgery irradiation area , head trauma adult , evidence pituitary hormone deficiency , idiopathic childhood onset GHD ( without know hypothalamic pituitary lesion injury ) . Healthy* control subject , match 'high likelihood GHD ' subject GH therapy within 1 month prior anticipate first GHST within trial ( within 3 month case longacting GH formulation ) . GHST within 7 day prior anticipate first test day within trial . Subjects euthyroid , subject change thyroid therapy within 8 week prior anticipate first test day within trial . Untreated hypogonadism stable substitution treatment within 30 day prior anticipate first test day within trial . Treatment drug directly affect pituitary secretion somatotropin ( e.g . somatostatin analogue , clonidine , levodopa , dopamine agonist ) provoke release somatostatin ; antimuscarinic agent ( atropine ) . Concomitant use CYP3A4 inducer ( e.g. , carbamazepine , phenobarbital , phenytoin , pioglitazone , rifabutin , rifampin , St. John 's Wort ) . Medical history ongoing clinically symptomatic severe psychiatric disorder . Parkinson 's disease . Cushing disease patient supraphysiologic glucocorticoid therapy within 30 day prior anticipate first test day within trial . Type 1 diabetes untreated poorly control Type 2 diabetes , define HbA1c &gt; 8 % . Body mass index ( BMI ) â‰¥ 40.0 kg/m2 . Participation trial investigational drug within 30 day prior trial entry . Vigorous physical exercise within 24 hour prior GHST within trial . Known hypersensitivity macimorelin insulin , constituent either preparation . Clinically significant cardiovascular cerebrovascular disease . Prolonged ECG QT interval , define QTc &gt; 500 msec . Concomitant treatment drug might prolong QT/QTc . Elevation laboratory parameter indicate hepatic renal dysfunction damage ( ASAT , ALAT &gt; 2.5 x ULN ; GGT , creatinine , bilirubin &gt; 1.5x ULN ) . Medical history seizure disorder . Known immunosuppression . Current active malignancy nonmelanoma skin cancer . Breastfeeding positive urine pregnancy test ( woman childbearing potential ) . Women childbearing age without contraception , hormonal contraception use condom spermicide use diaphragm spermicide Intra Uterine Device ( IUD ) . Lack ability willingness give inform consent . Anticipated nonavailability trial visits/procedures .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adult Growth Hormone Deficiency</keyword>
</DOC>